In the years after the introduction of life-saving insulin therapy for the treatment of diabetes, diabetic nephropathy emerged as a complication of chronic diabetes. 1, 2 Diabetic nephropathy has since metamorphosed from a clinical rarity to the single major cause of kidney failure in the industrialized world. Although tight glucose control and treatment of hypertension substantially delay the progression of diabetic nephropathy, 3, 4 the impact of these interventions will fail to stem the increased prevalence of renal failure projected over the next decade. 5 Inhibition of angiotensin action with converting enzyme inhibition or receptor blockade confers added protection beyond treatment of hypertension and hyperglycemia, 6, 7 but only modestly slows the progression. Furthermore, after nearly 20 yr of use, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers remain the only clinically validated approach to treat specifically diabetic nephropathy. In part, this is because of the huge cost of clinical trials required to register new medicines for the treatment of chronic kidney disease (approximately $100,000,000 per trial). Because of the size and duration of these trials (typically 3 to 5 yr), not only have we few drugs to treat diabetic kidney disease, but also relatively few pivotal trials have been initiated for new drugs to treat kidney disease.
Taking the gamble on a new medicine to treat kidney disease relies now more than ever on its positive effect on a biomarker, typically albuminuria, obtained during multidose phase II safety trials, but the end point required for drug registration is doubling of serum creatinine, institution of dialysis, or death. In light of this, is it too much to ask for an animal model of diabetic kidney disease in which the impact of a molecule on renal insufficiency can be validated preclinically? Here exists a notorious disconnect, because most studies of mouse and rat models of diabetic nephropathy focus on albuminuria and histopathology, not renal insufficiency, as end points. Perhaps this is because rodent models of diabetic nephropathy that exhibit renal insufficiency have only recently been reported, 8 -12 and these models are validated only partially. Regardless of these reasons, effect of therapeutics on renal histopathologic changes is not one that can be used in a clinical trial. Conversely, whereas overt albuminuria may be predictive of a decline in renal function in human kidney disease, the same significance cannot be attributed to albuminuria in rodent models of kidney disease.
In this regard, Yuzawa et al. 13 in this issue of JASN provide important evidence supporting the utility of a calmodulin transgenic FVB mouse model of diabetic nephropathy (called FVBove26). As previously reported by Zheng et al., 12 this model exhibits substantial and progressively increasing albuminuria as well as mesangial expansion, nodular glomerulosclerosis, and arteriolar hyalinosis. As in the previous report, the authors of this study also suggest this transgenic diabetic mouse exhibits a decline in renal function; however, analysis of the details of this assertion underscores the complexities of assessing renal function in diabetic mice. The authors unfortunately rely on an enzymatic measurement of serum creatinine to make their case. The measurement of serum creatinine in mice using either enzymatic methods or picric acidbased methods is complicated by the presence of substantial noncreatinine chromagens that contribute 50 to 500% of the measured serum creatinine compared with that determined using LC-MS/MS or HPLC methods. 14 -16 It is thus confusing that the serum creatinine was increased at the same time that the calmodulin transgenic mice were markedly hyperfiltering, as determined by creatinine clearance. Neither did serum creatinine progressively increase over time in untreated controls, as would be expected from a progressive disease such as diabetic nephropathy. This is in contrast to the modest decrease in GFR at 9 mo (measured by inulin clearance) reported in the previous article characterizing these calmodulin transgenic mice. 12 Also troubling is the conflicting observation that when FVB mice are made diabetic with low-dosage streptozotocin, there is little evidence of either histopathologic or functional features of diabetic nephropathy. 17 It is conceivable the reported nephropathy phenotype in FVBove26 mice is specific for the calmodulin transgene, rather than diabetic hyperglycemia per se, a possibility that could be readily addressed by determining whether insulin treatment corrects both hyperglycemia and the renal phenotype.
One feature of the FVBove26 mouse with diabetes is dramatic polyuria, which has been widely observed. 12, 13, 17 In the study by Yuzawa et al. 13 , these mice excreted Ͼ50 ml/d urine-approximately two times their body weight. 13 This degree of polyuria is associated with the development of hydronephrosis in mice and, because of the profound dilution of the urine, significantly complicates the quantification of urine creatinine and albumin excretion.
Despite these and the aforementioned caveats, the FVBove26 transgenic mouse exhibits several features consistent with more advanced changes of diabetic nephropathy, including nodular glomerulosclerosis and profound albuminuria. Whether this model develops renal insufficiency and will allow testing of prospective therapies on progressive renal insufficiency remains to be seen. Certainly, effects of therapeutics on histopathology and albuminuria are important, but for clinical development of drugs for human kidney disease, we must demonstrate preservation of renal function. Should we ask for less of the animal models on which the gamble for drug therapies rests? 
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